VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 56,000 Shares of Edwards Lifesciences Corporation $EW

VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 923,311 shares of the medical research company’s stock after buying an additional 56,000 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Edwards Lifesciences were worth $71,806,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. NewSquare Capital LLC grew its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the last quarter. Rakuten Securities Inc. increased its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in Edwards Lifesciences during the 2nd quarter valued at approximately $40,000. Finally, Riverview Trust Co raised its stake in Edwards Lifesciences by 44.5% during the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock valued at $40,000 after buying an additional 159 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $86.17 on Wednesday. The firm’s 50-day moving average price is $84.28 and its 200-day moving average price is $79.79. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a market cap of $50.01 billion, a PE ratio of 37.14, a PEG ratio of 3.91 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on EW shares. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Barclays reissued an “overweight” rating and set a $103.00 price objective (up from $99.00) on shares of Edwards Lifesciences in a research report on Monday, December 8th. Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Citigroup reiterated a “buy” rating and issued a $101.00 target price (up previously from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, Stifel Nicolaus set a $100.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $93.95.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,465 shares of company stock valued at $3,804,610 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.